{
    "brief_title": "To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study",
    "phase": "",
    "drugs": "['Pegylated liposomal doxorubicin', 'Epirubicin', 'Cyclophosphamid', 'Trastuzumab', 'Pertuzumab', 'Docetaxel']",
    "drugs_list": [
        "Pegylated liposomal doxorubicin",
        "Epirubicin",
        "Cyclophosphamid",
        "Trastuzumab",
        "Pertuzumab",
        "Docetaxel"
    ],
    "diseases": "['Breast Cancer']",
    "diseases_list": [
        "Breast Cancer"
    ],
    "enrollment": "204.0",
    "inclusion_criteria": "inclusion criteria: \n\n 18-70 years old, Female; \n\n Subjects with histopathologically confirmed invasive breast cancer; \n\n HER2-positive breast cancer (Immunohistochemistry score of 3+ or fluorescence in situ hybridization positivity); \n\n No distant metastasis; \n\n Lymph node positive or negative, primary tumour\u22652cm; \n\n Lymph node negative\uff0cprimary tumour\u22642cm and any of the following factors; 1) Histological grade 3; 2) ER negative (<10%) and PR negative (<20%); 3) Age<35 years old; 4) Pathological hint: vascular invasion or intravascular cancer thrombus; \n\n Surgery was completed and chemotherapy was started within 8 weeks after surgery; \n\n Before and after chemotherapy LVEF\u226555%; \n\n ECOG performance status of 0-1; \n\n Signed the informed consent. \n\n ",
    "exclusion_criteria": ": \n\n Subjects who are known to be allergic or intolerant to chemotherapy drugs or their excipients; \n\n Previously suffered from invasive breast cancer, and other malignant tumors within 5 years (excluding carcinoma in situ of the cervix, carcinoma in situ of the rectum, carcinoma in situ of melanoma, basal cell carcinoma of the skin, and squamous cell carcinoma); \n\n For breast cancer, have received any anti-tumor therapy before randomization (except surgical treatment before enrollment); \n\n Hematopoietic function, renal function and liver function meet one of the following conditions: 1) Neutrophil count \u22641.5\u00d7109/L; 2) Platelet count \u2264 50\u00d7109/L; 3) Hemoglobin \u2264 8.0g/dL; 4) Creatinine clearance rate \u226430ml/min; 5) AST and ALT \u2265 2.5 times the upper limit of normal in subjects without liver metastases; 6) Bilirubin \u2265 2 times the upper limit of normal; 7) APTT/PT\u22651.5 times the upper limit of normal; \n\n Have a history of cardiovascular disease or associated with severe cardiovascular disease, lung disease; \n\n Active hypertension: systolic blood pressure \u2265 180mmHg, diastolic blood pressure \u2265 90mmHg; \n\n NYHA cardiac insufficiency grading \u2265 \u2162 grade; \n\n Severe, uncontrollable systemic disease; \n\n Subjects who are pregnant or breastfeeding, or subjects who cannot ensure effective contraceptive measures during the study treatment; \n\n Subjects who participated in other clinical trials at the same time; \n\n Subjects determined by the investigator to be inappropriate to participate in this study.",
    "brief_summary": "To evaluate the safety and efficacy of pegylated liposomal doxorubicin/cyclophosphamide/trastuzumab/pertuzumab followed by docetaxel/ trastuzumab/pertuzumab compared with epirubicin/cyclophosphamide followed by docetaxel/trastuzumab/pertuzumab in the adjuvant treatment of early breast cancer.",
    "NCT_ID": "NCT05656079"
}